Last updated on: 25/06/2021
1. Contact details
Name of data sourceDeutsches Arzneiprüfungsinstitut
Name under which the data source should be displayed in the inventory (e.g short name if one exists)DAPI database
Name of organisation
1) Department/research groupDAPI
2) Organisation/affiliationDeutsches Arzneiprüfungsinstitut e.V. (DAPI)
Administrative Contact
Title Ms
Last name Werning
First name Johanna
Address line 1Heidestraße 7
Address line 2
Address line 3
CityBerlin
Postcode10557
CountryGermany
Scientific Contact
Title Ms
Last name Werning
First name Johanna
Address line 1Heidestraße 7
Address line 2
Address line 3
CityBerlin
Postcode10557
CountryGermany
Alternative Contact
Title Ms
Last name Kieble
First name Marita
Address line 1Heidestraße 7
Address line 2
Address line 3
CityBerlin
Postcode10557
CountryGermany
2. Description/category
Administrative database, e.g. claims database
Pharmacy dispensing database
3.1 Coverage of licensed medicinal products
Licensed Medicinal Product
Comments
Community / general practice data
3.2 ATC code (5th level)
Yes
3.3 Other product dictionaries
No
3.4 Recording of indication for use
No
4. Coverage of events
Event
Dictionary
Dictionary details
No events
5. Year of establishment
2005
6. Geographical origin of data
EEA/EFTA countries
Germany
7. Demographical extent of data collection
Nation-wide
8. Age groups
17 years and under [Paediatrics]
18 to 45 years
46 to 64 years
65 years and over
9. Size of the source/catchment population
70,000,000
10 a. Total (cumulative) number of persons with actual data
10 b. Number of persons with active data collection in past calendar year
11. Possibility to obtain additional information on the patient
a) Clinical information from treating physician?
No
b) Questionnaire data from the patient?
No
c) Genetic information or samples?
No
12. Possibility of links to other sources of data
No
13. Written policy governing data access
Yes
14. Committee to evaluate requests for data access
Yes
15. Charge/fee for data access
No
16. Selected publications of the last 5 calendar years using data from this data source
ReferenceLink to web-publication
Mahfoud F, Enners S, Kieble M, Werning J, Laufs U, Millenaar D, Böhm M, Kintscher U, Schulz M, “Dear Doctor” Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription, Dtsch Arztebl Int 2020, 117: 687-8https://doi.org/10.3238/arztebl.2020.0687
Gradl G, Teichert M, Kieble M, Werning J, Schulz M, Comparing outpatient oral antibiotic use in Germany and the Netherlands from 2012 to 2016, Pharmacoepidemiology and Drug Safety (2018), 27(12), p. 1344-1355https://doi.org/10.1002/pds.4643
Rudolph UM, Enners S, Kieble M, Mahfoud F, Laufs U, Schulz M, Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany, Journal of Human Hypertension (2020)https://doi.org/10.1038/s41371-020-00425-z
Hofmann GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B, The frequency of photosensitizing drug dispensings in Austria and Germany: a correlation with their photosensitizing potential based on published literature, JEADV (2020), 34(3), p. 589–600https://doi.org/10.1111/jdv.15952
Moorkens E, Barcina Lacosta T, Vulto AG, Schulz M, Gradl G, Enners S, Selke G, Huys I, Simoens S, Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany, Pharmaceuticals 2020, 13(10), 324https://doi.org/10.3390/ph13100324
